TY - JOUR
T1 - The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma
T2 - A Retrospective Multi-institutional Study
AU - Takamori, Shinkichi
AU - Toyokawa, Gouji
AU - Shimokawa, Mototsugu
AU - Kinoshita, Fumio
AU - Kozuma, Yuka
AU - Matsubara, Taichi
AU - Haratake, Naoki
AU - Akamine, Takaki
AU - Hirai, Fumihiko
AU - Seto, Takashi
AU - Tagawa, Tetsuzo
AU - Takenoyama, Mitsuhiro
AU - Ichinose, Yukito
AU - Maehara, Yoshihiko
N1 - Publisher Copyright:
© 2018, Society of Surgical Oncology.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Background: Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. Identification of clinical prognostic indicators is therefore needed. Although the C-reactive protein/albumin ratio (CAR) has been used to predict the prognosis of many types of malignancy, its utility in patients with MPM is unknown. Methods: The data of 100 patients diagnosed as having MPM from 1995 to 2015 at the National Kyushu Cancer Center and Kyushu University were analyzed. The CAR was calculated as serum C-reactive protein concentration divided by albumin concentration. A cutoff for CAR was set at 0.58 according to a receiver operating characteristics curve for 1-year survival. Results: Thirty-five of the 100 (35.0%) patients were classified as having a high CAR. A high CAR was significantly associated with advanced clinical stage (p < 0.001) and chemotherapy alone (p = 0.002). Patients with a high CAR had significantly shorter overall survival (OS) (p < 0.001) and disease- or progression-free survival (DFS/PFS) (p < 0.001). These associations between CAR and prognosis remained significant after propensity score-matching. In multivariate analysis, a high CAR was an independent predictor of shorter OS and DFS/PFS (p = 0.003 and p = 0.008, respectively). Multivariate analyses of the subgroups of patients who had received chemotherapy and of patients who had undergone surgery also showed that a high CAR was an independent predictor of shorter OS and DFS/PFS. Conclusions: CAR is an independent predictor of prognosis in MPM patients. This prognostic index contributes to clinicians’ ability to predict benefit from treatment. Further larger, prospective studies are necessary to validate these findings.
AB - Background: Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. Identification of clinical prognostic indicators is therefore needed. Although the C-reactive protein/albumin ratio (CAR) has been used to predict the prognosis of many types of malignancy, its utility in patients with MPM is unknown. Methods: The data of 100 patients diagnosed as having MPM from 1995 to 2015 at the National Kyushu Cancer Center and Kyushu University were analyzed. The CAR was calculated as serum C-reactive protein concentration divided by albumin concentration. A cutoff for CAR was set at 0.58 according to a receiver operating characteristics curve for 1-year survival. Results: Thirty-five of the 100 (35.0%) patients were classified as having a high CAR. A high CAR was significantly associated with advanced clinical stage (p < 0.001) and chemotherapy alone (p = 0.002). Patients with a high CAR had significantly shorter overall survival (OS) (p < 0.001) and disease- or progression-free survival (DFS/PFS) (p < 0.001). These associations between CAR and prognosis remained significant after propensity score-matching. In multivariate analysis, a high CAR was an independent predictor of shorter OS and DFS/PFS (p = 0.003 and p = 0.008, respectively). Multivariate analyses of the subgroups of patients who had received chemotherapy and of patients who had undergone surgery also showed that a high CAR was an independent predictor of shorter OS and DFS/PFS. Conclusions: CAR is an independent predictor of prognosis in MPM patients. This prognostic index contributes to clinicians’ ability to predict benefit from treatment. Further larger, prospective studies are necessary to validate these findings.
UR - http://www.scopus.com/inward/record.url?scp=85045059616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045059616&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6385-x
DO - 10.1245/s10434-018-6385-x
M3 - Article
C2 - 29500763
AN - SCOPUS:85045059616
SN - 1068-9265
VL - 25
SP - 1555
EP - 1563
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 6
ER -